Literature DB >> 9050897

Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models.

J P Steiner1, G S Hamilton, D T Ross, H L Valentine, H Guo, M A Connolly, S Liang, C Ramsey, J H Li, W Huang, P Howorth, R Soni, M Fuller, H Sauer, A C Nowotnik, P D Suzdak.   

Abstract

Although immunosuppressant immunophilin ligands promote neurite outgrowth in vitro, their neurotrophic activities are clearly independent of their immunosuppressive activity. In the present report, a novel nonimmunosuppressive immunophilin ligand, GPI-1046 (3-(3-pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate+ ++) is described. In vitro, GPI-1046 bound to FK506 binding protein-12 and elicited neurite outgrowth from sensory neuronal cultures with picomolar potency with maximal effects comparable to nerve growth factor. In vivo, GPI-1046 stimulated the regeneration of lesioned sciatic nerve axons and myelin levels. In the central nervous system, GPI-1046 promoted protection and/or sprouting of serotonin-containing nerve fibers in somatosensory cortex following parachloroamphetamine treatment. GPI-1046 also induced regenerative sprouting from spared nigrostriatal dopaminergic neurons following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice or 6-hydroxydopamine (6-OHDA) toxicity in rats. The rotational abnormality in 6-OHDA treated rats was alleviated by GPI-1046. These neurotrophic actions in multiple models suggest therapeutic utility for GPI-1046 in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050897      PMCID: PMC20035          DOI: 10.1073/pnas.94.5.2019

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  High brain densities of the immunophilin FKBP colocalized with calcineurin.

Authors:  J P Steiner; T M Dawson; M Fotuhi; C E Glatt; A M Snowman; N Cohen; S H Snyder
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

Review 2.  Chemistry and biology of the immunophilins and their immunosuppressive ligands.

Authors:  S L Schreiber
Journal:  Science       Date:  1991-01-18       Impact factor: 47.728

3.  Probing immunosuppressant action with a nonnatural immunophilin ligand.

Authors:  B E Bierer; P K Somers; T J Wandless; S J Burakoff; S L Schreiber
Journal:  Science       Date:  1990-10-26       Impact factor: 47.728

Review 4.  Chemical neurotoxins as denervation tools in neurobiology.

Authors:  G Jonsson
Journal:  Annu Rev Neurosci       Date:  1980       Impact factor: 12.449

5.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

6.  Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation.

Authors:  C J Woolf; Q P Ma; A Allchorne; S Poole
Journal:  J Neurosci       Date:  1996-04-15       Impact factor: 6.167

7.  Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment.

Authors:  M Hadjiconstantinou; N H Neff
Journal:  Eur J Pharmacol       Date:  1990-05-31       Impact factor: 4.432

Review 8.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Authors:  M Gerlach; P Riederer; H Przuntek; M B Youdim
Journal:  Eur J Pharmacol       Date:  1991-12-12       Impact factor: 4.432

9.  Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain.

Authors:  L A Mamounas; M E Blue; J A Siuciak; C A Altar
Journal:  J Neurosci       Date:  1995-12       Impact factor: 6.167

10.  The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.

Authors:  F J Dumont; M J Staruch; S L Koprak; J J Siekierka; C S Lin; R Harrison; T Sewell; V M Kindt; T R Beattie; M Wyvratt
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

View more
  35 in total

Review 1.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Design and structure-based study of new potential FKBP12 inhibitors.

Authors:  Fei Sun; Pengyun Li; Yi Ding; Liwei Wang; Mark Bartlam; Cuilin Shu; Beifen Shen; Hualiang Jiang; Song Li; Zihe Rao
Journal:  Biophys J       Date:  2003-11       Impact factor: 4.033

3.  FK506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway.

Authors:  Raymond D Price; Takayuki Yamaji; Nobuya Matsuoka
Journal:  Br J Pharmacol       Date:  2003-10-14       Impact factor: 8.739

4.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

6.  Erectile function outcomes in the current era of anatomic nerve-sparing radical prostatectomy.

Authors:  Arthur L Burnett
Journal:  Rev Urol       Date:  2006

7.  Neuroprotective and antiretroviral effects of the immunophilin ligand GPI 1046.

Authors:  Joseph P Steiner; David Galey; Norman J Haughey; Daniella Asch; Avindra Nath
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-03       Impact factor: 4.147

Review 8.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

9.  The effects of cold preservation and subimmunosuppressive doses of FK506 on axonal regeneration in murine peripheral nerve isografts.

Authors:  Terence M Myckatyn; Daniel A Hunter; Susan E Mackinnon
Journal:  Can J Plast Surg       Date:  2003

10.  Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities.

Authors:  Benfang Ruan; Kevin Pong; Flora Jow; Mark Bowlby; Robert A Crozier; Danni Liu; Shi Liang; Yi Chen; Mary Lynn Mercado; Xidong Feng; Frann Bennett; David von Schack; Leonard McDonald; Margaret M Zaleska; Andrew Wood; Peter H Reinhart; Ronald L Magolda; Jerauld Skotnicki; Menelas N Pangalos; Frank E Koehn; Guy T Carter; Magid Abou-Gharbia; Edmund I Graziani
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.